NASDAQ$TLRY
Tilray Brands Inc · Q2 2022 earnings
Q2 2022 earnings · · Investor relations
Briefing
Tilray reported a profitable second quarter with increased revenue and net income.
Tilray's Q2 2022 financial results showed a ~20% increase in net revenue to $155 million and a net income of $6 million, a $95 million improvement from the prior year quarter. The company also achieved $13.8 million in adjusted EBITDA, marking the 11th consecutive quarter of positive adjusted EBITDA.
- Net revenue increased ~20% to $155 million from the prior year quarter.
- Net income improved $95 million to $6 million from the prior year quarter.
- Adjusted EBITDA of $13.8 million, 11th consecutive quarter of positive Adjusted EBITDA.
- Achieved $70 million in cost synergies to date; On-Track to Exceed Original Plan of $80 Million Ahead of Schedule and to Generate Additional $20 Million of Synergies in Fiscal 2023.
Headline financials
Revenue & EPS history
Tilray · Revenue · Quarterly
$155M
Revenue by segment
Tilray · $155M total across 4 segments · Q2 2022
- Distribution$68.9M-6.9%44.4%
- Cannabis$58.8M+7.3%37.9%
- Wellness$13.8M—8.9%
- Beverage$13.7M—8.8%
Forward guidance
Tilray is on track to exceed its original synergy plan and generate additional synergies in fiscal year 2023. The company is also well-positioned to benefit from recreational legalization in Germany and to leverage its U.S. CPG platform for cannabis products upon federal legalization.
Tailwinds
- On-Track to Exceed Original Plan of $80 Million Ahead of Schedule and to Generate Additional $20 Million of Synergies in Fiscal 2023
- Leading Medical Cannabis Company in Europe with ~20% Market Share in Germany
- Tilray is also the only company currently supplying the German government with medical cannabis grown in-country.
- The Company’s state-of-the-art EU GMP certified cultivation facility in Germany has additional capacity to immediately support entry into the recreational market upon legalization, which the new German coalition government is accelerating.
- SweetWater, the 11th largest craft brewer in the nation and leading lifestyle brand, and Manitoba Harvest, a pioneer in hemp, CBD and wellness products.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q2 2022
-2.1%
Avg return
Earnings day
-4.2%
Avg return
5 days after
-3.5%
Avg return
30 days after
34%
11 / 32 earnings
Positive
+27.4%
Q4 2023
Best reaction
-22.0%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q3 2026 | -2.9% | -9.2% | — | |
| Q2 2026 | +0.2% | +8.4% | -17.0% | |
| Q1 2026 | +21.2% | -7.0% | -27.9% | |
| Q3 2025 | -21.2% | -15.5% | -24.1% | |
| Q2 2025 | -13.9% | -13.9% | -27.0% | |
| Q1 2025 | +0.0% | -3.7% | -8.6% | |
| Q4 2024 | +9.8% | +1.6% | -7.1% | |
| Q3 2024 | -22.0% | -29.7% | -23.6% | |
| Q2 2024 | -14.5% | -20.1% | -19.2% | |
| Q1 2024 | -5.4% | -9.4% | -14.3% | |
| Q4 2023 | +27.4% | +50.6% | +39.3% | |
| Q3 2023 | -3.1% | -8.8% | +5.8% | |
| Q2 2023 | -5.4% | +7.5% | +2.7% | |
| Q1 2023 | -21.3% | -21.0% | -2.3% | |
| Q4 2022 | +12.0% | +19.6% | +17.5% | |
| Q3 2022 | -7.8% | -9.4% | -32.6% | |
| Q2 2022 | +15.0% | +6.9% | +7.8% | |
| Q1 2022 | -2.8% | -4.7% | -0.8% | |
| Q4 2021 | +21.1% | +14.8% | +5.4% | |
| Q3 2021 | +1.4% | +0.1% | -16.8% | |
| Q4 2020 | -21.7% | -24.1% | -26.8% | |
| Q2 2021 | +4.3% | +10.2% | +109.7% | |
| Q3 2020 | -13.5% | -20.6% | -17.8% | |
| Q2 2020 | -7.1% | -2.8% | -24.3% | |
| Q1 2020 | -4.0% | -0.1% | +24.6% | |
| Q4 2019 | -9.8% | -30.6% | -59.1% | |
| Q3 2019 | -4.5% | -9.1% | -13.6% | |
| Q2 2019 | -8.1% | -26.3% | -28.0% | |
| Q1 2019 | +5.2% | -1.7% | -12.4% | |
| Q4 2018 | -3.7% | -7.4% | -30.1% | |
| Q3 2018 | -9.8% | -2.6% | -33.4% | |
| Q2 2018 | +16.3% | +22.0% | +145.7% | |
| Q1 2018 | — | — | — | |
| Q4 2017 | — | — | — | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — | |
| Q4 2016 | — | — | — | |
| Q3 2016 | — | — | — | |
| Q2 2016 | — | — | — | |
| Q1 2016 | — | — | — | |
| Q4 2015 | — | — | — | |
| Q3 2015 | — | — | — | |
| Q2 2015 | — | — | — | |
| Q1 2015 | — | — | — | |
| Q4 2014 | — | — | — | |
| Q3 2014 | — | — | — | |
| Q2 2014 | — | — | — | |
| Q1 2014 | — | — | — | |
| Q4 2013 | — | — | — | |
| Q3 2013 | — | — | — | |
| Q2 2013 | — | — | — | |
| Q1 2012 | — | — | — | |
| Q4 2012 | — | — | — | |
| Q3 2011 | — | — | — | |
| Q2 2011 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro